Last reviewed · How we verify
NCT06172699: Assert-IQ
Assert-IQ Implantable Cardiac Monitor (ICM) Post Market Study
trial testing Holter monitoring in patients who have been successfully implanted with an Abbott Assert-IQ ICM device in Atrial Fibrillation Paroxysmal in 150 participants. Participants enrolled and being followed up; not accepting new ones.
24 December 2024
Quick facts
| Lead sponsor | Abbott Medical Devices |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 1 January 2024 |
| Primary completion | 24 December 2024 |
| Estimated completion | 24 December 2025 |
| Sites | 11 locations across United States |
Drugs / interventions tested
- Holter monitoring in patients who have been successfully implanted with an Abbott Assert-IQ ICM device
Conditions studied
- Atrial Fibrillation Paroxysmal — all drugs for Atrial Fibrillation Paroxysmal →
- Atrial Fibrillation, Persistent — all drugs for Atrial Fibrillation, Persistent →
- Cardiac Arrhythmia — all drugs for Cardiac Arrhythmia →
- Ablation — all drugs for Ablation →
Sponsor
Abbott Medical Devices — full company profile →
Who can join
Adults 18 to 100, any sex, with Atrial Fibrillation Paroxysmal or Atrial Fibrillation, Persistent. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective, non-randomized, multi-center, real-world post-market study to collect and evaluate data regarding the performance of the enhanced atrial fibrillation detection algorithm of the Assert-IQTM Implantable Cardiac Monitor (ICM) device.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Atrial fibrillation detection performance of an insertable cardiac monitor: Results from an Assert-IQ post-market clinical study and a novel artificial intelligence algorithm.
Birgersdotter-Green U, Ojeda W, Manyam H, Garcia AM, et al · · 2026 · PMID 41695515 · DOI 10.1016/j.hroo.2025.10.021
Verify or expand the search:
- PubMed search for NCT06172699
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Atrial Fibrillation Paroxysmal
Currently open trials in the same condition.
- NCT06557876 — The Effect of Pulse Field Ablation on Atrial Mechanics in Catheter Ablation of Paroxysmal Atrial Fibrillation · NA · recruiting
- NCT06696170 — CellFX® Nanosecond Pulsed Field Ablation (PFA) 360 Catheter Ablation System for Treatment of Atrial Fibrillation · NA · recruiting
- NCT05549752 — Flecainide Versus Amiodarone in the Cardioversion of Paroxysmal Atrial Fibrillation at the Emergency Department, in Pati · Phase 3 · recruiting
- NCT05292209 — RiLuzole to Reduce Atrial FIb Study Using Holter Monitoring · Phase 2 · recruiting
- NCT04606693 — Value of Screening and Treatment of SAHS in the Management of AF Ablation Candidates · NA · recruiting
Other Abbott Medical Devices trials
Trials by the same sponsor.
- NCT07421076 — Grid eXplore Mapping Study · NA · recruiting
- NCT07509658 — TriClip Japan Post-Approval Study · recruiting
- NCT07361445 — Agilis RF TSP Early Feasibility Study · NA · recruiting
- NCT07373353 — A Clinical Evaluation of AMJ-401 · NA · recruiting
- NCT07217392 — Left Bundle Branch Area Pacing (LBBAP) PMCF Study · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06172699 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Abbott Medical Devices
- Last refreshed: 20 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06172699.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing